ALS launches Invitek Diagnostics

 

dna helix
09 MAY 2023 ALS
ALS Diagnostics, a provider of molecular diagnostics products, today announced the launch of Invitek Diagnostics. The move follows the acquisition of Invitek Molecular GmbH, a prominent player in the molecular diagnostics market, combined with ALS Diagnostics to form Invitek Diagnostics. With this launch, we now offer a joint portfolio under the same brand that covers the full spectrum of lab workflows: from sample to result.

According to Andreas Jonsson, ALS Executive General Manager of Food & Pharmaceutical, "The Invitek Diagnostics portfolio allows us to offer comprehensive solutions that meet the evolving needs of our customers. Invitek Diagnostics brand represents quality, innovation, and reliability, and this rebranding will provide a stronger and more recognizable presence in the market. Invitek Diagnostics will provide our customers an enhanced experience through a unified product portfolio, excellent client service, and fast delivery times."

The Invitek Diagnostics brand's launch reflects ALS' continued commitment to providing its customers with high-quality products, support, and services. The new brand will better reflect its capabilities and help establish it as a leader in the molecular diagnostics market. The changes will be visible on the Invitek.com website, product packaging, and supporting collateral in the coming weeks and months. 

"By bringing together the expertise of ALS and Invitek, we can offer our customers a more comprehensive range of products and services," adds Andreas Jonsson. "João Cotta will continue to lead this new business as Invitek Diagnostics Global General Manager. We are very excited about this new chapter in our journey and look forward to providing our customers with an enhanced experience through the Invitek Diagnostics people, products, and services."